menu ☰
menu ˟

Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer

18 Feb 2014

Brain metastasis (BM) is rare in colorectal cancer (CRC) patients. Although BM from CRC is a late-stage phenomenon with an extremely poor prognosis, some subsets of patients would benefit from a multidisciplinary management strategy. The prognosis of patients with BM from CRC was associated with the curability of the therapy for BM and the number of metastatic organs. Metastatic brain tumors are generally treated with radiotherapy because many anticancer drugs cannot cross the blood-brain barrier. Here, we present a case treated with XELOX (capecitabine and oxaliplatin) plus bevacizumab for BM from rectal cancer. To our knowledge, this is the first report of a patient who was successfully treated for BM from CRC without radiotherapy. The findings could lead to a paradigm shift in the use of chemotherapy for BM from CRC. © 2014 S. Karger AG, Basel
Case Rep Oncol 2014;7:117-121

Date: 
18 February 2014

Click here to view the full article which appeared in Case Reports in Oncology

IPH Logo